TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03909256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NUTRI-HAB
Description: The rehabilitation program is a coordinated multidisciplinary effort involving several specialists e.g. clinical dietitians, nurses, physiotherapists, occupational therapists (responsible for dysphagia management in Denmark), psychologists and social workers.~The program includes group sessions with patient education on how to handle the different aspects of living with eating problems and other late effects. Practical kitchen exercises, physical activity sessions and instruction in swallowing training are included. Individual counseling sessions with clinical dietitians and other health professionals (e.g. physicians) are offered depending on participants' needs.~Participants stay at the premises and all meals throughout the day are served in the dining room or in the café. Foods of different textures and flavors are served to inspire participants and to allow them to experiment.~Between the initial stay and follow-up participants are contacted twice by a clinical dietitian.
Study: NCT02302820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advance Care Planning Intervention
Description: ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advance Care Planning Intervention
Description: ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advance Care Planning Intervention
Description: ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advance Care Planning Intervention
Description: ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids.
Study: NCT00587054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
Description: Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.~Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines.
Study: NCT00056966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H
Description: Day -8 through Day -6 Dosed per Institutional SOP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Description: Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
Study: NCT00521014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Study: NCT03204903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Subjects were treated 3 times per week for 12 weeks with the LaserPen (GaAlAs laser diode, 810 nm, 150 mW, pulsed waves), which delivered 0.375 J of energy (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: Subjects were treated 3 times per week for 12 weeks with the LaserPen without laser output (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
Study: NCT02865928

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Same injection technique as intervention arm with normal saline
Study: NCT03609710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transanal tube placement
Description: Transanual tube placement after anastomosis in low anterior resection for rectal cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left colic artery preservation
Description: Left colic artery preservation during operation for lower rectal cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anastomotic reinforcing sutures
Description: Anastomotic reinforcing sutures during operation for lower rectal cancer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic surgery
Description: Robotic low anterior resection for rectal cancer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: Robotic low anterior resection for rectal cancer
Study: NCT03152110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: A handcycle or tabletop ergometer will be used for HIIT. Exercise sessions will be scheduled 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.~Supervised exercise sessions: Measures include HR, BP, RPEs, Feeling Scale, and PPO. After warming up, individualized work/rest phases will be prescribed based on their PPO from their maximal aerobic test. Participants will be held at 90% PPO as a constant target intensity to start, shortening the work phase, and if necessary, lengthening the recovery phase. These parameters will be progressed each session. The trainer will determine when to change their work/rest parameters based off of HR and RPEs.~Unsupervised exercise sessions: Participants will repeat the same HIIT protocol they performed during the previous supervised session. The bike computer automatically stores HR and PPO.
Study: NCT02082665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin10 mg tablet
Description: Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg syrup
Description: Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib 75 mg capsule
Description: Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
Study: NCT01905514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: internet mobile application
Study: NCT05155839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG001
Description: Administrated intravenously
Study: NCT03304392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized ICBT
Description: An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard ICBT
Description: An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
Study: NCT01901367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: Receive nutritional intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Receive exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow-up care
Description: Receive booster follow-up sessions from the nutritionist and exercise physiologist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Receive phone counseling with a trained health coach

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT04630444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: 30 PTSD patients with riluzole 100 mg daily (50 mg bid).
Study: NCT01634100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Probenecid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: BI Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: BI Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Probenecid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin (BI 10773)
Description: BI Drug
Study: NCT00744692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unrelated Umbilical Cord Blood Transplant
Description: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning
Study: NCT00997828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everolimus-eluting stent
Description: Xience V stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary artery bypass graft surgery
Description: coronary artery bypass graft surgery
Study: NCT01934608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Refill synch
Study: NCT02911051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actreen Hydrolite Cath
Description: Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
Study: NCT02768844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic Vibrotactile Stimulation (SVS)
Description: The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available; designed by Wyss Institute, Harvard University, Cofab Design LLC) to provide gentle vibrations and sounds during mattress stimulations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Absence of mattress Stochastic Vibratory Stimulation (SVS)
Study: NCT01140464

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative care
Description: Provision of depression care management in the primary care setting to improve delivery of evidence based treatments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Provision of screening results to provider, teen and parent with recommendation to seek further care
Study: NCT04410835

Intervention type: DIAGNOSTIC_TEST
Intervention: Online Survey
Description: Psychological questionnaires

Intervention type: DIAGNOSTIC_TEST
Intervention: Online Survey
Description: Psychological questionnaires
Study: NCT00959894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (Intelence)
Description: Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
Study: NCT03965546

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sorafenib combined with ET140202-T cell
Description: 1. Sorafenib starting dose of 400mg b.i.d. a.c.~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAE combined with ET140202-T cell
Description: 1. Transarterial embolization(TAE) treatment~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET140202-T cell
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)
Study: NCT04391153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with tissue sampling
Description: Patients with biliary strictures undergo ERCP o EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with tissue sampling
Description: Patients with biliary strictures undergo ERCP o EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
Study: NCT01902836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus DLE
Description: Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:~Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment plus placebo
Description: Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
Study: NCT02982642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1612 capsule
Description: Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
Study: NCT00427375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local rectal excision
Description: New surgical option in good responders after neoadjuvant treatment for low rectal cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total mesorectal excision
Description: standard surgery
Study: NCT00952419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 Influenza vaccine
Description: 0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 Influenza vaccine
Description: 0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution (placebo)
Description: 0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
Study: NCT04162912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing tailored Advance Care Planning
Description: The trained interventionist who is experienced in MI techniques will explore their illness experiences, emotions and beliefs about their health conditions and future care in an empathetic manner and explore their ambivalence for ACP behaviours.
Study: NCT04955197

Intervention type: DIAGNOSTIC_TEST
Intervention: exfoliated cytology
Description: Micronuclei (MN) are small chromatin bodies in the cytoplasm formed by chromosome fragments or whole chromosomes that fail to be included in the nuclei during cell division. They are considered as a sensitive indicators of genetic damage. They are usually found in the basal cells of epidermis and are shed as exfoliated cells on maturation. Hence micronuclei assay can be used as monitoring of genetic damage, as it is increased in oral neoplastic conditions. Consequently, detection of micronuclei in exfoliated cells indicates an increased risk for cancer
Study: NCT02954731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UP-CBT
Description: Psychotherapy in groups based on the Unified Protocol a third generation CBT-type psychotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-CBT
Description: Psychotherapy in groups based on diagnosis specific, manualized, cognitive behavior therapy
Study: NCT01312272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive placebo nasal spray
Description: A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.